Story · Medicine & Biotech

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

2 outlets · first reported by STAT News on · latest · 3 hours of coverage · 2 countries

The Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved… (STAT News)

Coverage, in order

  1. first STAT News indie study
    STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

    The Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved…

  2. Pharmaphorum UK indie
    FDA won't approve Summit, Akeso's ivonescimab

    FDA won't approve Summit, Akeso's ivonescimab Phil.Taylor Sun, 15/11/2026 - 18:23

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.